# Episode 507: ASCO 2026 - TALAPRO-3

Page: https://stenobird.com/podcast/the-uromigos-1214845/episode-507-asco-2026-talapro-3
Text version: https://stenobird.com/podcast/the-uromigos-1214845/episode-507-asco-2026-talapro-3.md
Podcast: [The Uromigos](https://stenobird.com/podcast/the-uromigos-1214845)
Published: 2026-05-30T23:30:00+00:00
Episode link: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-507-ASCO-2026---TALAPRO-3-e3jqvme
Audio file: https://anchor.fm/s/13347ea8/podcast/play/120470670/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-24%2F424794338-44100-2-6d6e4c9015d05.m4a
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-507-asco-2026-talapro-3
Duration seconds: 2505

## Resource

Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-507-asco-2026-talapro-3/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-uromigos-1214845/episode-507-asco-2026-talapro-3.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.